Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
Zhigang Liu, James L. Alexander, Kaixing Le, Xin Zhou et autres
8 citationsEClinicalMedicine